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All cellular proteins are synthesized by ribosomes,
whose biogenesis in eukaryotes is a complex multi-
step process completed within minutes. Several
chemical inhibitors of ribosome function are available
and used as tools or drugs. By contrast, we lack
potent validated chemical probes to analyze the
dynamics of eukaryotic ribosome assembly. Here,
we combine chemical and genetic approaches to
discover ribozinoindoles (or Rbins), potent and
reversible triazinoindole-based inhibitors of eukary-
otic ribosomebiogenesis. AnalysesofRbin sensitivity
and resistance conferring mutations in fission yeast,
alongwith biochemical assayswith recombinant pro-
teins, provide evidence that Rbins’ physiological
target is Midasin, an essential 540-kDa AAA+ (AT-
Pases associated with diverse cellular activities) pro-
tein. Using Rbins to acutely inhibit or activateMidasin
function, in parallel experiments with inhibitor-sensi-
tive or inhibitor-resistant cells, we uncover Midasin’s
role in assembling Nsa1 particles, nucleolar precur-
sors of the 60S subunit. Together, our findings
demonstrate that Rbins are powerful probes for
eukaryotic ribosome assembly.INTRODUCTION
Everyminute a growing cell can generate2,000 ribosomes, ribo-
nucleoprotein-basednanomachines that translate information en-
coded in the genome to synthesizeproteins (Thomsonet al., 2013;
Tschochner and Hurt, 2003;Warner, 1999). The assembly of ribo-
somes, which contain 5,500 nucleotides of RNA and 80 pro-
teins that are together organized into the 60S and 40S subunits,
starts in the nucleolus with the transcription of rDNA. Subsequent
steps lead to the processing of RNA to generate 25S, 5.8S, and
5S rRNAs (ribosomal RNAs) for the 60S subunit and the 18S
rRNA for the 40S subunit. These steps are coupled to the ordered512 Cell 167, 512–524, October 6, 2016 ª 2016 Elsevier Inc.association and dissociation of several different ribosomal and
non-ribosomal proteins to formpre-ribosomal subunits that accu-
mulate in thenucleus.Properly assembledprecursors are thenex-
ported to the cytoplasm, where the final processing steps lead to
functional ribosomes (Thomsonet al., 2013; Tschochner andHurt,
2003). Currently, it is unclear how such elaborate spatial and tem-
poral coordination of the several steps required for ribosome as-
sembly is achieved by 200 non-ribosomal proteins (Thomson
et al., 2013; Tschochner and Hurt, 2003). This is in large part due
to the lack of tools and approaches to analyze this essential and
dynamic cellular process.
The assembly of the 60S subunit involves multiple intermedi-
ates, collectively referred to as pre-60S particles (Nissan et al.,
2002). The rearrangements of these particles have been charac-
terized using imaging and immunoprecipitation-based ap-
proaches, and the key intermediates have been linked to specific
proteins that associate with distinct particles, such as the Nsa1-
associated complex (named the Nsa1 particles) assembled in
the nucleolus and the Rix1-associated complex (named the
Rix1 particles) processed in the nucleoplasm (Kressler et al.,
2012). The fidelity of this dynamic assembly process depends
on precise spatial and temporal regulation at each stage. For
example, a Nug2 GTPase-dependent checkpoint blocks export
of pre-60S particles to the cytoplasm until it is properly assem-
bled (Matsuo et al., 2014). The sequential processing of these
ribosome assembly intermediates requires numerous energy-
consuming enzymes, including ATPases in the AAA+ (ATPases
associated with diverse cellular activities) family (Kressler et al.,
2012; Thomson et al., 2013).
The AAA+ family is a large and functionally diverse group of
enzymes that can couple ATP hydrolysis with mechanical work
(e.g., protein unfolding or directional transport) (Erzberger and
Berger, 2006; Hanson and Whiteheart, 2005). At least three
AAA+ ATPases, Drg1, Rix7, and Midasin (Rea1 in S. cerevisiae
and Mdn1 in S. pombe), are involved in the assembly of the
60S subunit (Kressler et al., 2012). Drg1 and Rix7 are closely
related to the well-studied Cdc48 (p97/VCP in mammals) and
likely function as homohexamers with six equivalent ATPase
sites (Patel and Latterich, 1998). By contrast, Midasin has all
six ATPase domains within a single long polypeptide, an organi-
zation that is similar to that of the microtubule-based motor
protein cytoplasmic dynein (Kressler et al., 2012). Midasin’s
ATPase domains form a ring-like domain from which extends
an elongated ‘‘tail’’ with a Metal Ion-Dependent Adhesion Site
(MIDAS) domain at its end (Garbarino and Gibbons, 2002; Ul-
brich et al., 2009). Currently, the ATPase activity of Midasin,
one of the largest proteins in yeast, has not been characterized,
and it is unclear whether all of its ATPase domains are essential
for ribosome biogenesis.
Our current models for Midasin function in 60S biogenesis are
based in large part on studies of the S. cerevisiae ortholog, Rea1.
Knockdown of Rea1 in budding yeast leads to the accumulation
of pre-60S particles in the nucleus (Galani et al., 2004). Rea1’s
nucleoplasmic function has been linked to the Rix1 particles,
where Rea1 is enriched (Galani et al., 2004; Nissan et al., 2002;
Nissan et al., 2004). Rea1 interacts with Rsa4, another non-ribo-
somal protein present in the Rix1 particles. Overexpression of an
Rsa4 mutant that fails to interact with Rea1 causes dominant-
negative defects in 60S biogenesis (Ulbrich et al., 2009).
In vitro experiments show that ATP addition can dissociate
Rsa4, Rea1, and Rix1 from the Rix1 particles pulled down from
wild-type cells, but not from cells overexpressing Rea1 with mu-
tations in its AAA domain or the MIDAS domain (Matsuo et al.,
2014; Ulbrich et al., 2009). Rea1 also interacts with Ytm1, a
non-ribosomal protein that mainly associates with nucleolar
Nsa1 particles, precursors of the Rix1 particles (Bassler et al.,
2010). These data, together with additional studies of the Rix1
particles and Rea1 (Ulbrich et al., 2009), have led to a model in
which ATP hydrolysis-dependent motion of Rea1’s ‘‘tail’’ leads
to dissociation of Rsa4 from nucleoplasmic pre-60S particles
and Ytm1 from nucleolar pre-60S particles (Kressler et al.,
2012). However, in order to dissect Midasin’s functions in living
cells, we need acute inhibition so that we can distinguish be-
tween direct effects of Midasin inhibition from cumulative
defects resulting from blocking earlier stages of ribosome
biogenesis. This is particularly important as conventional genetic
analyses, using temperature-sensitive strains or overexpression
of dominant-negative mutants, suppress protein function over
hours, while many steps of ribosome biogenesis are completed
within minutes.
Cell-permeable chemical inhibitors can be powerful tools
for examining dynamic cellular processes, such as ribosome
biogenesis, as the functions of target proteins can be blocked
within minutes. Currently, the only known chemical inhibitor
that directly targets eukaryotic ribosome assembly factors is di-
azaborine, an antibacterial compound active only at 0.4 mM in
S. cerevisiae (Loibl et al., 2014), a concentration at which selec-
tive target inhibition may be difficult to achieve. Moreover,
because diazaborine blocks cytoplasmic steps (i.e., pre-60S
maturation) of ribosome biogenesis, we lack chemical probes
for the several distinct assembly steps that occur in the nucleolus
and nucleus. Lamotrigine is another chemical inhibitor of ribo-
some assembly factors that has been recently described (Stokes
et al., 2014). However, this compound has been shown to only
block ribosome biogenesis in E. coli at low temperatures (Stokes
et al., 2014).
In this study, we identify ribozinoindoles (or Rbins), as potent,
reversible, and specific inhibitors of Midasin. Systematic ge-
netic analyses of Rbins’ sensitivity and RBins’ resistance infission yeast, along with biochemical characterization of Mdn1’s
ATPase activity, indicate that Rbins directly and specifically inhibit
Mdn1 function in vitro and in cells. We combine microscopy,
biochemical approaches, and the use of Rbins to inhibit or acti-
vate Midasin on the timescale of minutes to analyze ribosome as-
sembly dynamics. Our findings uncover a previously uncharacter-
ized function of Midasin in assembling nucleolar Nsa1 particles.
RESULTS
Discovery of Rbin-1Using a ‘‘Chemical Synthetic Lethal’’
Screen
To identify cell-permeable chemical probes of essential cellular
processes, we have developed fission yeast as a model system
that allows us to efficiently combine genetic and chemical ap-
proaches (Aoi et al., 2014; Kawashima et al., 2012). In particular,
we have generated fission yeast strains (named ‘‘MDR-sup’’
strains) lacking critical factors for multi-drug resistance (or
MDR) and have used them for chemical screens that mimic syn-
thetic lethal genetic screens (Kawashima et al., 2012, 2013). We
hypothesized that compounds that reveal enhanced toxicity to
strains with a particular mutation, compared to a control strain,
are likely to be more selective for a single protein target. Consis-
tent with this hypothesis, our use of this strategy identified a se-
lective inhibitor for Aurora kinase, a key cell-cycle regulator (Ka-
washima et al., 2013). From a similar chemical synthetic lethal
screen carried out with a 10,353-member library of diverse
chemicals, we identified a triazinoindole-based heterocycle,
which we named ribozinoindole-1 (or Rbin-1), that was more
toxic to the MDR-sup cells that contained a mutation in cut2,
compared to those with a wild-type cut2+ or a mutation in cut1
(Figures 1A and 1B). Both Cut1 and Cut2 are essential proteins
needed for faithful chromosome segregation (Funabiki et al.,
1996). Subsequent analyses indicated that Rbin-1’s ‘‘synthetic
lethality’’ was not due to a chromosome mis-segregation
(‘‘cut’’) phenotype (Figure 1C). In addition, we found that sensi-
tivity to the cut2 mutant was also observed in strains with the
wild-type background (Figure S1A), but reverting the cut2muta-
tion to wild-type cut2+ did not suppress Rbin-1 sensitivity (Fig-
ures 1D and S1B). Together, these data indicate that the
increased sensitivity to the chemical inhibitor was due to other
‘‘background’’ mutations that were likely introduced when the
mutant strain was first generated (Hirano et al., 1986).
To examine the mode of action of Rbin-1, we backcrossed
the cut2 mutant MDR-sup strain with wild-type cut2+ MDR-sup
and then analyzed the entire genome for mutations. Sequencing
analysis identified four genes (SPCC737.08, SPAC14C4.01c,
SPAC26A3.01, and SPAC26A3.05) bearing mutations, among
which we found that a point mutation (Leu1113Phe) in the mdn1
(SPCC737.08) gene confers sensitivity to Rbin-1, but not cyclo-
heximide (Figures 1E, S1C, and S1D), suggesting that Rbin-1
may target Mdn1 or cellular processes that involve this protein.
To further address themode of action of Rbin-1, we chemically
mutagenized the MDR-sup fission yeast cells and isolated resis-
tant clones that can grow in the presence of Rbin-1. Each of the
13 Rbin-1 resistant clones contained one of five different point
mutations in themdn1 gene (Figure 1E). In separate experiments
using a PCR-based random mutagenesis strategy, we isolatedCell 167, 512–524, October 6, 2016 513
two additional mdn1 mutations that confer Rbin-1 resistance
(Figure 1E). We next confirmed, using overexpression on plas-
mids in MDR-sup cells and by replacement of endogenous
mdn1 in wild-type cells, that all the mutations we identified
were sufficient to confer resistance to Rbin-1 (Figures 1F, 1G,
and S1E). Importantly, these mutations did not confer resistance
to cycloheximide, another chemically unrelated inhibitor (Fig-
ure 1F). Interestingly, all seven of these resistance-conferring
mutations and the sensitivity-conferring mutation clustered
around two (AAA3 and AAA4) of the six AAA domains in Mdn1
(Figure 1E). Together, our findings indicate that different muta-
tions in Mdn1 can either enhance or suppress Rbin-1’s activity
in both MDR-sup and wild-type cells. Hereafter, for further
studies, we use fission yeast strains with the wild-type back-
ground rather than the MDR-sup strains.
Structure-Activity Analyses Lead to a More Potent
Rbin-1 Analog
We next optimized the chemical inhibitor’s potency by gener-
ating a focused collection of analogs. Twenty-three compounds
were synthesized by condensing isatin (or derivatives) with hy-
drazinecarbothioamide and further elaborated using haloge-
nated aliphatic and aromatic moieties (Figure 1H). This proced-
ure yielded Rbin-1 analogs in >95% purity and 7%–65%
overall yield (see Supplemental Information). Dose-dependent
analyses were used to determine the potency of these analogs
in growth assays (Figure 1I: data for selected compounds; and
Figures S2A and S2B: full dataset). Our studies reveal that alkyl
substituents at the 3-thiol position result in compounds with ac-
tivities that are reduced compared to that of Rbin-1 (Figure S2A).
A benzyl moiety at the 3-thiol position increased potency but
reduced solubility. Larger aromatic substitutions at this position
reduced compound activity (Figures 1I and S2). A homo-prop-
argyl modification at the indole nitrogen (R2 position) also re-
sulted in an inactive analog (Figure 1I). We found that the most
striking changes in activity resulted from modifications of the
A-ring (Figure 1I). In particular, an analog (Rbin-2) with a bromine
substituent at postion-7 was 10-fold more active than Rbin-1
(GI50 = 14 ± 1 nM (Rbin-2); 136 ± 7 nM (Rbin-1), n = 4, mean ±
SD, Figure 1I). In contrast, an iodine substituent at position-8
suppressed activity (Figure 1I). We confirmed that Rbin-2 activity
against the strain expressing the resistance-conferring mutation
(mdn1-F1093L) was substantially reduced, while activity against
the strain expressing the sensitivity-conferring mutation (mdn1-
L1113F) was increased relative to the wild-type strain (Fig-
ure S2D). Together, these tests identify Rbin-2 as a potent
Rbin-1 analog that is likely to have a similar mechanism of action.
At Least Four of the Six ATPase Sites in Mdn1 Are
Required for Growth
The findings that mutations in mdn1 substantially alter com-
pound sensitivity indicate Rbins could directly target Mdn1,
possibly by inhibiting its ATPase activity. As in other AAA+ pro-
teins, ATP binding in Mdn1 is likely to be at the interface of two
AAA domains and involves Walker A and B motifs from one
AAA domain while the arginine finger motif extends from the
following AAA domain (e.g., ATP binding at the AAA1 site de-
pends on Walker A1, Walker B1, and the arginine finger R2 mo-514 Cell 167, 512–524, October 6, 2016tifs) (Figures 2A and 2B) (Erzberger and Berger, 2006). Sequence
alignment of Mdn1 homologs across different species, from
yeast to human, showed that key motifs required for ATPase ac-
tivity, including Walker A, Walker B, and Arginine Finger, are
highly conserved for the AAA2-AAA5 sites (Kressler et al.,
2012). AAA1 and AAA6 have conserved Walker A motifs but
not Walker Bmotifs, suggesting that their ATP hydrolysis activity
may not be required for Mdn1 function (Figure 2D). However, in
contrast to dynein (Carter, 2013), the contributions of each
ATP-binding site in Mdn1 have not been characterized.
To address which ATP-binding pockets are essential for
Mdn1’s functions, we established an ‘‘mdn1-ts complementa-
tion assay,’’ in which different Mdn1 mutants are overexpressed
in an mdn1 temperature-sensitive (ts) mutant strain and the
growth at the restrictive temperature is measured. To develop
this assay, we first generated an mdn1 temperature-sensitive
mutant strain (mdn1-ts26, Figures 2C, S3A, and S3B). We found
that I3280M is the critical mutation that causes temperature
sensitivity, since reversing only this mutation (I3280M was
mutated to the original isoleucine) abolished temperature sensi-
tivity (mdn1ts26-IMI in Figure 2C). We then generated the
different ATPase mutants and expressed them in the mdn1-
ts26 strain (Figure 2D). Analysis of Walker A mutants showed
that the A1 mutant suppressed temperature sensitivity of
mdn1-ts26 cells, similar to wild-type Mdn1, while others
(A2–A6) did not (Figure 2E). Walker B mutants B2, B3, B4, and
B5 failed to complement temperature sensitivity of the mdn1-
ts26 mutant (Figure 2E). Analyses of the arginine finger, which
in the case of R2, R3, R4, and R6 can be two arginines and for
R5 only one, showed that the double arginine to alanine R2
mutant suppressed temperature sensitivity of mdn1-ts26 cells,
while other mutants (R3–R6) did not (Figure 2E). Further analyses
show that the second arginine residues at R3, R4, and R6 are
critical for Mdn1’s functions (Figure 2F). As key residues in B1,
B6 and R1 motifs are not conserved, they were not examined
by mutagenesis. Together, these data suggest that the ATPase
activity of AAA2, AAA3, AAA4, and AAA5 and ATP-binding ability
of AAA6 are likely essential for Mdn1’s cellular functions.
Characterization of Mdn1 ATPase Activity In Vitro
ATP hydrolysis by Midasin has not been demonstrated thus far.
To analyze Mdn1’s ATPase activity and examine inhibition by
Rbin-1, we needed to purify Mdn1 for in vitro biochemical as-
says. We tried different constructs and recombinant protein
expression systems, including bacteria and yeast. A tandem-af-
finity protocol similar to the one used to purify recombinant Rea1
from budding yeast (Ulbrich et al., 2009) did not yield full-length
fission yeast Mdn1. Finally, we employed the insect cell system
to generate recombinant Mdn1. After significant optimization,
we developed a multi-step strategy, which included nickel affin-
ity, ion exchange, and size-exclusion chromatography (Fig-
ure 3A). In the final purification step, Mdn1 eluted from a size-
exclusion column at a volume (10.6 mL, Void: 7.5 mL) consistent
with its large size (mol wt 542 kDa for hexahistidine-tagged
Mdn1) and extended shape based on analyses of Rea1 (Figures
3B and 3C) (Nissan et al., 2004; Ulbrich et al., 2009). A typical pu-
rification yielded 0.1 mg of recombinant Mdn1 per 3 L cell cul-
ture. Mass spectrometry confirmed that the single band resolved
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by SDS-PAGEwasMdn1, as we were able to identify 339 unique
peptides that covered >70% of the Mdn1 sequence (Figure 3D).
In particular, the identified peptides confirmed the presence of
80 amino acids at Mdn1’s C terminus. These data along with
the N-terminal tag-based isolation indicate that we are able to
purify full-length recombinant Mdn1.
To test recombinant Mdn1’s ATPase activity, we first analyzed
the hydrolysis of radio-isotope labeled ATP. We found that the
levels of ATPase activity closely matched the elution profile of
Mdn1 from size-exclusion chromatography (Figure 3B, red
trace). We next examined the steady-state ATPase activity of
Mdn1 using an NADH-coupled enzyme assay. The specific ac-
tivity of Mdn1 was 1.0 s–1 at 1 mM MgATP (Figure 3E). These
data indicate that Mdn1 is an ATPase with specific activity com-
parable to that of other AAA+ proteins, such as VPS4 and dynein
(Kon et al., 2004; Yang et al., 2015).
Rbins Inhibit Recombinant Mdn1’s ATPase Activity
In Vitro
We next examined inhibition of Mdn1’s steady-state ATPase ac-
tivity by Rbin-1 and analogs. Two of the active analogs (Rbin-1
and Rbin-2) inhibited the ATPase activity by 40% at 1 mM (Fig-
ure 3E). Under similar conditions, analogs that were inactive in
cell-based assays did not suppress ATPase activity (Figure 3E).
As the amounts of Mdn1 were limiting, we focused on the dose-
dependent inhibition of Mdn1 activity by Rbin-2, the most potent
analog. While increasing concentrations of Rbin-2 resulted in
greater inhibition, the dose-dependent inhibition saturated at
50%, consistent with inhibition of a subset of the ATPase do-
mains in Mdn1. For the observed dose-response curve, we
can estimate an apparent EC50 (0.3 mM, Figure 3F). For com-
parison, we find that almost complete inhibition of the ATPase
activity (in a radioactive assay) can be achieved by a non-hydro-
lyzable ATP analog (AMPPNP, 2 mM), while Rbin-1 (1 mM) only
inhibited activity by40% (Figure 3G). The difference in potency
of Rbins in in vitro ATPase and cell-based assays could be due to
at least two reasons. First, full activity of Mdn1 may be needed
for cell growth, and therefore partial inhibition (for exampleFigure 1. Characterization of Rbin-1, a Potent Chemical Inhibitor of Ce
(A) MDR-sup (WT), MDR-sup cut1-22 (cut1ts), and MDR-sup cut2-364 (cut2ts) cel
(%) is presented relative to DMSO-treated cells (mean ± SD, n = 3 independent
(B) Chemical structure of Rbin-1.
(C) Nuclear morphology of MDR-sup cells (WT), MDR-sup cut1-22 (cut1ts) and M
MDR-sup cells treated with 10 mM Rbin-1 at 29C for 2.5 hr (+Rbin-1) were exam
temperature-sensitive cut1 or cut2 mutants, are highlighted (yellow arrowheads)
(D) cut2-364 (cut2ts) and a cut2ts-rev strain (with the cut2-364 mutation reverted
concentrations of Rbin-1 at 29C or untreated at 37C. Growth (%) is presented
pendent experiments).
(E) Domain organization of the S. pombe Mdn1 protein (Sp Mdn1). The AAA do
Locations of a Rbin-1 sensitivity-conferringmutation (red), Rbin-1 resistance confe
resistance-conferring mutations obtained using a chemical mutagen (blue) are in
(F) Serial dilutions of the indicated mdn1 mutants were spotted onto YE4S plate
2 days.
(G) Wild-type and indicatedmdn1mutants were incubated for 17 hr at 29C with i
treated cells (mean ± range, n = 2 independent experiments).
(H) General synthesis scheme for RBin analogs (R1X: halogenated alkyl/aryl subs
(I) Activity of Rbin analogs. Wild-type cells were incubated with Rbin analogs (18 h
experiments) was determined by fitting relative growth to a four-parameter sigm
A summary of all the strains used is provided in Table S1. See also Figures S1 a
516 Cell 167, 512–524, October 6, 201615%) by Rbins could suppress growth. Second, the recombinant
protein may not faithfully recapitulate the activity of the native
protein, which may be post-translationally modified or could be
in a complex with other proteins (e.g., Rsa4 in Rix1 particles)
that may modulate activity or inhibition.
To more firmly establish that Mdn1 is Rbins’ direct target, we
generated full-length recombinant Mdn1 containing a mutation
(F1093L) that confers resistance to the Rbins in cell-based as-
says (hereafter, Mdn1-F1093L, Figures 3H and S4). We find
that Mdn1-F1093L is an active enzyme whose ATPase activity
(1.5 ± 0.2 ATP s–1) in the steady-state assay is comparable to
that of wild-type Mdn1. Importantly, Rbin-2 does not strongly
suppress the ATPase activity of the Mdn1-F1093L (Figure 3F).
Together, these data establish what we refer to as ‘‘gold stan-
dard’’ proof that the physiological target of Rbins is Mdn1, as
the same single mutation can suppress inhibition by Rbins in
both cell-based and in vitro biochemical activity assays (Wacker
et al., 2012).
Rbin-1 Allows Inhibition of Mdn1-Dependent Pre-60S
Ribosome Biogenesis in Fission Yeast Cells on Fast
Timescales
Guided by studies of Rea1 in S. cerevisiae, we examined Mdn1
function in S. pombe by taking advantage of Rbin-1 and ge-
netics. We first examined pre-rRNA processing and the nuclear
export of the pre-60S subunit. The defects in pre-rRNA process-
ing were observed in Rbin-1-treated cells and in amdn1 temper-
ature-sensitive mutant strain (Figure S5), as observed in budding
yeast lacking Rea1 function (Galani et al., 2004). Importantly,
these defects were not observed in Rbin-1-treated mdn1-
F1093Lmutant strains (Figure S5), indicating that the phenotype
in Rbin-1-treated cells depends on Mdn1 inhibition. We also
found that nuclear export of the pre-60S subunit, which can be
tracked using Rpl2501-GFP, a homolog of budding yeast
Rpl25 (Hurt et al., 1999), was blocked in Rbin-1-treated cells
(Figures 4A and 4B). Importantly, this defect was not observed
in Rbin-1-treated mdn1-F1093L mutant cells (Figure 4A). This
defect was also observed at the restrictive temperature in all Growth
ls were incubated with different concentrations of Rbin-1 (17 hr, 29C). Growth
experiments, trace: interpolation).
DR-sup cut2-364 (cut2ts) cells at 36C for 2.5 hr (restrictive temperature), and
ined. Representative images are shown. Cells with cut phenotype, observed in
. Scale bars, 10 mm.
to wild-type cut2+) (see also Figure S1B) were incubated (17 hr) with indicated
relative to DMSO-treated cells incubated at 29C (mean ± range, n = 2 inde-
mains, linker, Asp/Glu-rich region (D/E) and MIDAS domain are highlighted.
rringmutations obtained by error-prone PCRofmdn1 gene (green), andRbin-1
dicated.
, or YE4S plate containing indicated compounds, and incubated at 29C for
ndicated concentrations of Rbin-1. Growth (%) is presented relative to DMSO-
titutent R2: substituent at position-5 of B-ring nitrogen).
r, 29C). Half maximum growth inhibition (GI50, mean ± SD, n = 3 independent
oidal dose-response curve in PRISM.
nd S2.
AC
D
F
E
B Figure 2. Analyses of the Contributions of
Midasin’s ATPase Sites to Cell Growth
(A) Schematic for Mdn1’s ATPase domains. The
different Walker A (An, n = 1–6), Walker B (Bn), and
arginine finger (Rn) motifs, which could be readily
identified, are indicated.
(B) Model for the AAA3 (gray)-AAA4 (yellow) do-
mains of dynein shows the nucleotide-binding site
(PDB: 4AKH; AMPPNP: magenta). Selected resi-
dues are highlighted (Walker A lysine, blue; Walker
B glutamate, green; arginine finger, red).
(C) Temperature sensitivity of the indicated strains
was examined.
(D) Primary sequence for the Walker A, Walker B,
and arginine finger motifs from each of Mdn1’s six
AAA domains are shown. Residues mutated for
experiments in (E) and (F) are highlighted (red).
(E and F) Exponentially growing culture of mdn1-
ts26 strains in which wild-type (WT) or indicated
mutants of full-length Mdn1 or vector control (–)
was overexpressed from the nmt1 promoter in the
absence of thiamine were incubated for 24 hr
(36C). Growth (%) is presented relative to WT-
overexpressed cells (mean ± SD, n = 4 indepen-
dent experiments, each bar graph shows data for
mutant- or WT-overexpressing cells tested side by
side). For R finger mutants, RARA indicates that
both arginines in thismotif aremutated to alanines,
and 1st or 2nd indicates that the first or second
arginine is mutated to alanine.
A summary of all the plasmids used is provided in
Table S2. See also Figure S3.mdn1 temperature-sensitive mutant strain (Figure 4C). In
contrast, the nuclear export of the pre-40S subunits that were
tracked using two different reporters, Rps2-GFP and Rps3-
GFP (Galani et al., 2004), was not blocked in Rbin-1-treated cells
(Figure 4D), indicating that Mdn1 has specific roles in pre-60S
ribosome assembly. Further, by comparing Rpl2501-GFP withGar1-mCherry (nucleolus marker) and
DAPI (DNA marker), we found that pre-
60S particles accumulated in the nucle-
olus upon Mdn1 inhibition (Figures 4B
and 4C).
To examine the kinetics of ribosome as-
sembly inhibition by Rbin-1, we examined
Rpl2501-GFP levels at specific timepoints
after inhibitor addition or washout. Upon
Rbin-1 treatment the Rpl2501-GFP signal
accumulated in the nucleolus within
30 min and reached a maximum level in
90–120 min (Figures 4E and 4F). Relief
from Rbin-1 treatment revealed stepwise
reductions in the nucleolar signal, with
Rpl2501-GFP levels reducing substan-
tially (47%) within 5 min of washout and
then another 37% between 20 and
30 min and 15% between 40 and
60min (Figures 4E and 4F).We also exam-ined time-dependent defects in the processing of rRNA interme-
diates in Rbin-1-treated cells. The pre-rRNAs, such as 35S, 27S,
and 7S pre-rRNA, accumulated only after 60 min of Rbin-1 treat-
ment, reaching a maximum level 90–120 min after treatment (Fig-
ures 4G and 4H). The stepwise changes in Rpl2501-GFP levels in
the nucleolus, observed upon RBin treatment or washout, alsoCell 167, 512–524, October 6, 2016 517
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Figure 3. Rbins Inhibit Mdn1’s ATPase Activity In Vitro
(A) Schematic for strategy used to purify recombinant full-length Mdn1.
(B) The size-exclusion chromatography profile for Mdn1 (black trace). The activity of different fractions from this chromatography step was analyzed using a
radioactive ATPase assay ([MgATP] = 0.1 mM). Activity was normalized to the most active fraction (red dots, each fraction; trace, interpolation).
(C) SDS-PAGE analysis of purified full-length Mdn1 (WT) (Coomassie stain).
(D) Peptides identified by mass spectrometry of the purified protein are indicated (green bars, schematic generated using Proteome Discoverer 1.4, Thermo
Scientific).
(E) Mdn1’s activity in the presence of Rbin analogs (1 mM) was tested using an NADH-coupled ATPase assay ([MgATP] = 1 mM). The relative activity is indicated
(mean ± range, n = 2 independent experiments).
(F) Dose-dependent inhibition of the steady-state ATPase activity of wild-type Mdn1 and Mdn1(F1093L) by Rbin-2 (mean ± SD, n = 4 independent experiments).
An apparent EC50 was estimated for the inhibition of wild-typeMdn1 using a sigmoidal dose-response curve. Using similar equations, we were unable to properly
fit the small decrease in activity of Mdn1(F1093L) across the concentration range tested. Unpaired t test (without Welch’s correction) of the measured activity for
WT andMdn1(F1093), at the highest three inhibitor concentrations tested, indicate that the difference in values are statistically significant (p = 0.0020 (at 16.7 mM),
p = 0.0021 (at 3.33 mM), and p = 0.0019 (at 1.0 mM)).
(G) The ATPase activity of Mdn1 in the presence Rbin-1 (1 mM) or AMP-PNP (2 mM) using the radioactive ATPase assay (MgATP = 0.1 mM). Error bars show SD
(n = 6 independent experiments).
(H) SDS-PAGE analysis of purified full-length Mdn1(F1093L) (Coomassie stain).
See also Figure S4.suggest that Midasin inhibition can lead to the accumulation of
distinct intermediates of ribosome assembly.
Analysis of Mdn1-Dependent Assembly of the Rix1
Particles in Fission Yeast
We next examined the roles of fission yeast Mdn1 in processing
a well-characterized ribosome assembly intermediate, the Rix1
particle (Bassler et al., 2010; Ulbrich et al., 2009). Affinity purifica-
tion of Rix1-5FLAG showed that Mdn1 is associated with the
Rix1 particle (Figure S6A). In addition, similar to observations in518 Cell 167, 512–524, October 6, 2016budding yeast (Ulbrich et al., 2009), we find that fission yeast
Mdn1 interacts with Rsa4 through conserved MIDAS-MIDO do-
mains in a two-hybrid assay (Figure 5A). In comparison, similar
analysis suggests that the interaction of fission yeast Ytm1
withMdn1 is weaker than theMdn1-Rsa4 interaction (Figure 5A).
In budding yeast, a point mutation of Rsa4 (E114D) that
abolishes Rea1-Rsa4 interaction shows dominant-negative
phenotypes (Ulbrich et al., 2009). In contrast, we found that
overexpression of fission yeast Rsa4 with a point mutation
(E105D), which abolishes Mdn1-Rsa4 interaction, did not show
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Figure 4. Chemical and Genetic Perturbations Indicate the Midasin Is Required for Nuclear Export of Pre-60S Particles and Pre-rRNA
Processing in Fission Yeast
(A) Rpl2501-GFP signals in wild-type (WT) and mdn1-F1093L cells with or without Rbin-1 treatment (1 mM) were examined. Scale bar, 10 mm.
(B) Rpl2501-GFP signals (green) were compared with nucleolar marker Gar1-mCherry (red) and DNA (blue). Scale bar, 2 mm.
(C) Rpl2501-GFP signals in mdn1-ts26 cells at 25C or 36C for 6 hr were examined. Also shown are images of Rpl2501-GFP (green), Gar1-mCherry (red), and
DNA stained with DAPI (blue). Scale bar, 2 mm.
(D) The localization of markers for the 40S pre-ribosome, Rps2-GFP and Rps3-GFP (green, overlaid on the corresponding differential interference contrast [DIC]
image, red), was examined in the presence or absence of Rbin-1 (1 mM). Scale bar, 2 mm.
(E and F) Rpl2501-GFP localizationwas examined in asynchronous cells (0min), 1 mMRbin-1-treated cells (30–120min), and in cells after washing out Rbin-1 (wo-
5-60min) at 29C. Representative images are shown in (E). Scale bar, 10 mm. The signal intensity of Rpl2501-GFP in the nucleolus wasmeasured in (F). Average is
indicated by black bar (n = 80 cells). Asterisks indicate unpaired two-tailed Student’s t test significance value: ***p < 0.001.
(G) Schematic for pre-rRNA processing. The position of the northern blot probe, which can detect 35S/32S, 27S (27SA and 27SB), and 7S, is marked (blue line).
(H) Northern blot (for 35/32S, 27S, and 7S) and GelRed staining (for 25S, 18S, and 5.8S) of total RNA.
See also Figure S5.
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Figure 5. Analysis of Mdn1-Dependent Assembly of the Rix-1 Particles in Fission Yeast
(A) Two-hybrid assay for the interaction between S. pombe Mdn1 MIDAS (4301–4717 amino acids [aa]) and S. pombe Rsa4 MIDO domain (1–144 aa, with or
without E105D mutation) or S. pombe Ytm1 MIDO domain (1–93 aa).
(B) Wild-type cells, in which wild-type (WT) or mutant (E105D) full-length Rsa4, or vector control (pRep1) were overexpressed from nmt1 promoter, were streaked
on plates. Thiamine (Thi) addition represses transcription from nmt1 promoter.
(C–E) Whole-cell extracts (Input) were prepared from wild-type (WT) and mdn1-ts26 (ts) cells (incubated for 6 hr at 36C) or wild-type cells treated with Rbin-1
(1 mM) for indicated times. Rix1-5FLAG was immunoprecipitated with anti-FLAG antibodies (IP: FLAG). The indicated proteins ([C] GFP-Rsa4, [D] Ytm1-3HA, [E]
GFP-Rsa4) and Rix1-5FLAG were analyzed by SDS-PAGE and western blotting. The grouping of images from different parts of the same gel is indicated by
dividing lines. The graph in (E) shows relative amount of Rsa4 in IP samples (mean ± range, n = 2).
See also Figure S6.dominant-negative phenotypes (Figure 5B). Our data suggest
that Mdn1-Rsa4 interaction is conserved between two yeasts
but is likely not essential for fission yeast ribosome biogenesis.
Studies inS. cerevisiae predict that Rsa4 should be enriched in
the Rix1 particle upon Mdn1 inhibition, as Mdn1 activity is
required for the removal of Rsa4 from this pre-60S intermediate
(Ulbrich et al., 2009). However, unexpectedly, we find that the
amount of Rsa4 in Rix1 particles decreased at the restrictive
temperature in our fission yeast mdn1-ts strain (Figure 5C). In
addition, we find that Rsa4 levels were reduced in the Rix1 par-
ticles in fission yeast cells treated with Rbin-1 (Figure 5C). Simi-
larly, Rix1-bound Ytm1 also decreased in mdn1-ts and Rbin-1-
treated cells (Figure 5D). In a time-course experiment, we were
able to detect 15 min after inhibitor treatment a slight increase
in Rsa4 levels in the Rix1 particles (Figure 5E), consistent with
a role for Mdn1 in removing Rsa4 from this pre-60S assembly in-
termediate. In comparison, Ytm1 levels in the Rix1 particles were
largely unchanged at this time point (15 min, Figure S6B). How-
ever, at later time points the levels of Ytm1 and Rsa4 decreased
(Figures 5C–5E), consistent with findings using the mdn1-ts520 Cell 167, 512–524, October 6, 2016strain. Together, these data support a role for Mdn1 in proper
Rix1-particle assembly, and the time-dependent changes
following Rbin treatments are consistent with Mdn1 contributing
to more than one 60S-subunit processing step.
Mdn1 Is Required for the Assembly of the Nucleolar
Nsa1 Particles
We considered the possibility that Mdn1 contributes to nucleolar
ribosome assembly steps that precede the formation of the
nucleoplasmic Rix1 particle. One of the characterized nucleolar
pre-60S particle in budding yeast is the Nsa1 particle that con-
tains several assembly factors, such as Rix7, Ppp1, and Ytm1
(Kressler et al., 2012). We first examined the localization of
Nsa1 particle-associated proteins in untreated and Rbin-1-
treated cells. Rix7, Ppp1, Ytm1, and Nsa1 predominantly local-
ized in the nucleolus of growing fission yeast cells (Figures 6A
and 6B). Intriguingly, we find that Rix7 and Ppp1, but not Ytm1
and Nsa1, mislocalized in Rbin-1-treated cells (Figures 6A and
6B). We further examined the kinetics of Rix7 localization upon
Mdn1 inhibition and activation and found that Rbin-1 treatment
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Figure 6. Mdn1 Is Required for the Assembly of the Nucleolar Nsa1 Particles
(A and B) Rix7-GFP, Ppp1-GFP, Ytm1-GFP, and Nsa1-GFP signals in wild-type cells with or without Rbin-1 (1 mM, 1 hr at 25C) treatment were examined.
Representative images are shown in (A). Scale bar, 2 mm. The intensity of GFP signals in the nucleolus (NL) divided by that in nucleoplasm (NP) is shown in (B).
Mean ± SEM, n = 30 cells.
(C andD) Rix7-GFP signalswere examined in asynchronous cells (0min), 1 mMRbin-1-treated cells (30–120min), and cells after washing out Rbin-1 (wo-5-60min) at
29C. Representative images are shown in (C). Scale bars, 2 mm. The intensity of the Rix7-GFP signal in the nucleolus (NL) divided by that in the nucleoplasm (NP) is
shown in (D). Average is indicated by black bar (mean ± SEM, n = 30 cells). Asterisks indicate unpaired two-tailed Student’s t test significance value: ***p < 0.001.
(E–I) Whole-cell extracts (Input) were prepared from wild-type or mdn1-F1093L cells treated with Rbin-1 (1 mM) for indicated time. Nsa1-5FLAG was immuno-
precipitated with anti-FLAG antibodies (IP: FLAG). The indicated proteins ([E] Rix7-GFP, [F] Ppp1-GFP, [G] Ytm1-3HA, [H] Rix7-GFP, and [I] GFP-Mdn1) and
Nsa1-5FLAG were analyzed by SDS-PAGE and western blotting. The grouping of images from different parts of the same gel is indicated by dividing lines. The
graph in (H) shows relative amount of Rix7 in IP samples (mean ± range, n = 2).
See also Figure S7.for 30 min resulted in maximum observed change in the nucleo-
plasmic Rix7 signal, and, within 5 min after washing out Rbin-1,
Rix7 redistributed (Figures 6C and 6D). The rapid reduction of the
fluorescence signal illustrates the fast timescales of Rbin-1 ac-tion. In addition, these data suggest a role for Mdn1 in ribosome
assembly steps that precede the formation of the Rix1 particle.
We next purified and analyzed the Nsa1 particles in Rbin-1-
treated cells and compared them to untreated controls. TheCell 167, 512–524, October 6, 2016 521
Figure 7. Model for Mdn1’s Functions during the Assembly of the 60S Subunit of the Ribosome
In the nucleolus, Mdn1 binds to the pre-60S particle containing Nsa1 and Ytm1 (Nsa1 particle) and helps recruit Rix7, another AAA+ protein. Mdn1-dependent
removal of Ytm1 allows pre-60S particles to exit the nucleolus, andMdn1-dependent removal of Rsa4 from the Rix1 particle allows pre-60S particles to leave the
nucleoplasm.amount of Rix7 and Ppp1 in the Nsa1 particles was significantly
reduced by Rbin-1 treatment, while the amount of Ytm1 in the
Nsa1 particle remained relatively constant (Figures 6E–6G and
S7A). Importantly, a Rbin-1-resistant mdn1-F1093L mutation
suppressed these changes (Figures 6E and 6F), indicating that
the phenotypes due to Rbin-1 treatment depended on Mdn1
inhibition. Time-course experiments show that Rix7 reduction
was detected within 15 min after Rbin-1 treatment (Figure 6H).
Consistent with a role for Mdn1 in Nsa1-particle assembly, we
find that Mdn1 is present in this particle in fission yeast (Figure 6I;
Figures S7B and S7C). Further, Rbin-1 treatment substantially
reduced the levels of Mdn1 in the Nsa1 particle (Figure 6I). The
amount of Mdn1 co-purified with Nsa1 was less than that pulled
downwith Rix1 (Figure S7B), suggesting amore transient or sub-
stoichiometric association. Taken together, these data suggest
that Mdn1 activity is required for maintaining Mdn1 itself in the
nucleolar Nsa1 particle, where Mdn1 may help recruit ribosome
assembly factors, such as Rix7 and Ppp1 (Figure 7).
DISCUSSION
In this study, we report the discovery of ribozinoindoles, potent
and selective chemical inhibitors for Midasin, an essential
AAA+ protein required for eukaryotic ribosome biogenesis.
Matched inhibitor-sensitive and inhibitor-resistant cells allow
systematic analyses of dose-dependent target-specific effects
of the chemical probe, addressing a major potential limitation
of the use of chemical inhibitors to examine cellular mechanisms.
Further, the fast timescale of Mdn1 inactivation and activation by
Rbins is well suited to dissect Mdn1’s role in coordinating the
spatial and temporal dynamics of ribosome biogenesis.
Eukaryotic ribosome biogenesis involves complex multi-step
RNA processing, the recruitment of ribosomal proteins and dy-
namic associations of multiple non-ribosomal proteins (Thomson
et al., 2013). Briefly, two rRNA precursors, the 35S and the pre-
5S, are transcribed in the nucleolus. The 35S RNA is processed
to generate the 27S RNA that is subsequently cleaved to generate
25.5S and 7S RNAs. These RNAs contain sequences corre-
sponding to the 25S and 5.8S rRNAs present in the mature 60S
subunit. Findings from studies in budding yeast suggest that522 Cell 167, 512–524, October 6, 2016Mdn1/Rea1 is involved in two steps of ribosome biogenesis. First,
Mdn1/Rea1 removes Ytm1 from pre-60S particles likely before
the cleavage of an internal transcribed spacer (ITS2) from the
27S RNA. This step is needed for the exit of pre-60S particles
from the nucleolus to the nucleoplasm (Bassler et al., 2010). Sec-
ond, Mdn1/Rea1 dissociates Rsa4 from the pre-60S particles in
the nucleoplasm, before or during the processing of 7S pre-
rRNA (Ulbrich et al., 2009). This Mdn1/Rea1 function is needed
for the pre-60S particles to be exported from the nucleoplasm
to the cytoplasm (Bassler et al., 2010; Ulbrich et al., 2009) (Fig-
ure 7). Similar to what has been found in budding yeast for
Rea1, S. pombeMdn1 can interact with Rsa4 and Ytm1 through
conserved MIDAS-MIDO domains. In addition, consistent with
this model, we find that both 27S and 7S pre-rRNA processing
steps and export of pre-60S particles from the nucleolus are
blocked in Rbin-1-treated fission yeast cells. Finally, the rapid,
though transient, increase of Rsa4 in the Rix1 particle upon
Rbin-1 treatment supports the proposed function of Mdn1/Rea1
at this step of ribosome biogenesis. Together, these data indicate
that many aspects of Mdn1/Rea1-dependent ribosome biogen-
esis are likely to be conserved across fungi.
Our studies in fission yeast also suggest an additional role for
Mdn1 during ribosome biogenesis. We propose that Mdn1 con-
tributes to the assembly of the Nsa1 particles in the nucleolus
based on the following three lines of evidence. First, Rix7 and
Ppp1 have reduced association with the Nsa1 particles upon
Mdn1 inhibition. Second, we observe activity-dependent associ-
ation of Mdn1 with the Nsa1 particles. Third, upon Rbin-1 treat-
ment, key ribosome assembly factors that bind the Nsa1 parti-
cles, such as Rix7 and Ppp1, disperse in the nucleus rather
than accumulate in the nucleolus. Analysis of Rpl2501-GFP sig-
nals in Rbin-1-treated cells suggests that pre-60S particles are
mainly accumulated in the nucleolus upon loss of Mdn1 function
(Figure 4B). Therefore, the mislocalization of Rix7 and Ppp1 is
likely due to the loss of Mdn1-dependent association of these
proteins with the nucleolar pre-60S particles. Studies in budding
yeast indicate that Ytm1 is enriched in the Nsa1 particles among
distinct pre-60S particles in the nucleus (Bassler et al., 2010; Ul-
brich et al., 2009). As Ytm1 levels in the Nsa1 particle are not
changed upon Mdn1 inhibition (Figure 6G), we propose that
Mdn1 has a specific function in pre-60S processing in the nucle-
olus, after Ytm1 associates with the Nsa1 particle and before
Ytm1 is removed from the particle by Mdn1 (Figure 7). Additional
work is needed to identify the specific nucleolar pre-60S precur-
sor that contains Ytm1, Rix7, Ppp1, and Mdn1.
Importantly, the timescale of Midasin inactivation and activa-
tion by Rbin-1 (5–15 min) is significantly faster than what we
can achieve using genetic approaches (3–6 hr using our tem-
perature-sensitive allele). In particular, the temporal control
over target function that we can achieve with these chemical
probes is evident from studies of Rpl2501 and Rix7 localization,
which are altered in cells within 5 min of inhibitor washout (Fig-
ures 4 and 6). Analyses of the timescales over which different
phenotypes accumulate following chemical inhibitor treatments
can guide interpretations and help develop models for target
protein function in a dynamic, ordered, multi-step cellular pro-
cess, such as eukaryotic ribosome biogenesis. For example,
immediately after Rbin-1 treatment the levels of Rsa4 in Rix1
particles increase (Figure 5E), consistent with the proposed
function of Mdn1 in the assembly of these pre-60S particles (Ul-
brich et al., 2009). However, after prolonged chemical inhibition,
or genetic suppression of Mdn1 in fission yeast, Rsa4 levels in
the Rix1 particles drop (Figures 5C and 5E), observations that
do not support the proposed model. Importantly, we find reduc-
tion in Rsa4 levels in the Rix1 particles after Rbin-1 treatment
requires more time than the reduction of Rix7 in the Nsa1 parti-
cles. Therefore, it is likely that inhibition of the ‘‘upstream’’ Nsa1-
particle assembly leads to defects that accumulate and alter the
flux of pre-60S precursors and indirectly, over extended time,
impact the levels of proteins, such as Rsa4, associated with
Rix1. Developing a precise order of assembly and disassembly
for proteins during ribosome biogenesis will require additional
biochemical characterization of ribosome assembly intermedi-
ates. There are several technical issues, such as the composi-
tional heterogeneity of particles isolated using single tag-based
purifications, which need to be addressed. For example, it re-
mains unclear how many distinct sub-particles containing Rix1
exist in the nucleolus and nucleoplasm. It is likely that Rbins,
which allow acute and reversible inhibition of Mdn1, will help
dissect these fast assembly dynamics.
Midasin and the closely related motor protein dynein are the
only known members of the AAA+ protein family that have all
six AAA domains on a single polypeptide, a feature that likely al-
lows functional specialization of each of the multiple AAA do-
mains (Carter, 2013). In the case of dynein, which has been
extensively studied over the last couple of decades, two of its
ATPase sites contribute to the overall ATP hydrolysis and direc-
tional transport activity (Carter, 2013). As Rbin resistance and
sensitivity conferring mutations cluster proximal to one ATP
binding site in Mdn1, we favor the possibility that Rbins act
through inhibiting the activity of the ATPase site formed by
AAA3 and AAA4 domains. Consistent with this proposal, we
find that mutations of Walker A, Walker B, or Arginine-finger res-
idues at this ATPase site suppress cell growth. If Rbins target
only a single ATPase site in Mdn1, our data suggest that this
ATPase site contributes to half of the total activity and the other
sites contribute to the remainder. Additional structural and
biochemical studies will be needed to test this hypothesis.Our discovery of a specific and potent chemical inhibitor of
Midasin, along with the findings that dynein and p97/VCP can
be selectively inhibited by cell-permeable low-molecular-weight
compounds (Anderson et al., 2015; Chou et al., 2011; Firestone
et al., 2012), indicates that drug-like inhibitors can be developed
for AAA+ proteins. These discoveries lay the foundation for
developing pharmacophore models for rationally designing
chemical inhibitors for AAA+ proteins for which we lack chemical
probes, such as proteins involved in DNA replication, mitochon-
drial function, or cytoskeleton organization.
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Antibodies
Mouse monoclonal anti-GFP Roche Cat# 11814460001
Mouse M2 monoclonal anti-FLAG Sigma Cat# F3165
Mouse 12CA5 monoclonal anti-HA abcam Cat# ab16918
Chemicals, Peptides, and Recombinant Proteins
Cycloheximide Sigma Cat# C7698
Rbin-1 and analogs (see General Synthesis Information) synthesized N/A
Roche Complete, EDTA-free Protease Inhibitor Roche Cat# 11873580001
Critical Commercial Assays
DIG Northern Starter Kit Roche Cat# 12039672910
Experimental Models: Organisms/Strains
See Table S1 for S. pombe strains This paper N/A
S. cerevisiae: AH109 strain Masayuki Yamamoto lab (NIBB) N/A
Recombinant DNA
pDUAL-YFH1c-mdn1 Minoru Yoshida lab (RIKEN) N/A
Software and AlgorithmsCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by Tarun M. Kapoor (kapoor@mail.rockefeller.
edu) at the Rockefeller University.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
S. pombe
All strains usedare listed in TableS1. Standardgrowth conditions andmethodswereused (Morenoet al., 1991).Most experimentswere
performed in yeast extract (YE) medium containing adenine, leucine, uridine, and histidine. All plasmids used are listed in Table S2. To
overexpressMdn1by the nmt1promoter, pRep1-basedplasmidswere transformed into host strain, and transformantswere incubated
in minimal medium (EMM) without thiamine and leucine for over 15 hr. PCR-based gene targeting (Ba¨hler et al., 1998) was used to
construct gene deleted and fluorescent protein-tagged strains with selection marker gene cassettes. The MDR-sup strain is an engi-
neered drug-sensitive fission yeast, in which 7 MDR genes were inactivated (Aoi et al., 2014; Kawashima et al., 2012). For generating
mdn1-ts26 < < kanr strain, PCR-based random mutagenesis was performed. The 10 kb DNA fragment containing mdn1 Linker, D/E
rich, and MIDAS domains, along withmdn1 30-UTR and kanMXmarker, was amplified by LA Taq (Takara). The PCR reaction was per-
formed for 45cycles to introducemutations. The amplifiedDNA fragmentwas used for transformationofh90 leu1 ade6-M216 strain, and
colonies that formedat25Cbutnot at 36Cwere isolated. Forgeneratingmdn1-ts26-IMI<<kan, themdn1-ts26 strainwas transformed
using the 1 kb DNA fragment containing the wild-type I3280 codon sequence, followed by isolation of survivors at 34C. For generating
kan <<mdn1-L1113F strain, DNA fragment containing kan < <mdn1-L1113Fwas transformed into h+ ade6-M210 leu1 ura4-D18 strain,
and G418-resistant colonies were selected. The mdn1-L1113F mutation was confirmed by sequencing. To construct rpl2501-GFP
strain, DNA fragment containing leu1N(the first 150bp)-Padh1-rpl2501-GFP-Tnmt1-ura4
+-leu1C (the last 150bp) was transformed into
h- ura4-D18 strain, and Ura+ Leu colonies were selected. To construct the GFP-mdn1 strain, the DNA fragment carrying ura4+-
Pnmt1-GFP-linkerwas integrated at the downstreamofmdn1 promoter (Pmdn1) in the genomeby homologous recombination, followed
by deletion of the ura4+-Pnmt1 region using the DNA fragment containing Pmdn1-GFP and isolation of FOA-resistant transformants.
METHOD DETAILS
Chemical synthetic lethal screen
SAK84andSAK236strains (TableS1)wereused for thechemical genetic screen. Thechemical libraries thatwereused for screenwere
described previously (Takemoto et al., 2016). The MDR-sup strains are better suited for chemical screens as lower concentrations of
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compounds can be used than what is needed when using wild-type strains. Logarithmically growing cells (OD = 0.5) were diluted
50-fold,mixedwith compounds (2 mM) andYEmedium (total volume: 50 ml per well), and incubated for 15 hr at 29C.MultidropCombi
(Thermo Scientific) was used to dispense the cells into wells of the 384-plate (Greiner clear flat bottom PS plate). The growth was
measured using a microtiter plate reader (Perkin-Elmer EnVision, 590 nm filter). For calculation of growth ratios, OD values of each
well were divided by that of control well incubated with DMSO. From 10,353 compounds, we identified 6 compounds, including
Rbin-1, that were more toxic to the cut2-364 strain than the wild-type strain.
Isolation and construction of Rbin-1-resistant mdn1 mutants
For mdn1 mutagenesis, the SAK72 (Table S1) was transformed with mdn1 fragment (1-4378bp) amplified by error-prone PCR, and
spread onto plates containing 5 mM Rbin-1. 11 resistant clones were isolated. Sequencing of these clones revealed that all resistant
clones had a point mutation (D1123E: 9 clones, and E1187K: 2 clones) in themdn1 gene. For unbiasedmutagenesis, the SAK72 strain
treated with 1-methyl-3-nitro-1-nitrosoguanidine (NTG) in TM buffer (50 mM Tris, 50 mM Maleic acid, 7.5 mM (NH4)2SO4, 0.4 mM
MgSO4$7H2O [pH 6.0]) for 30 min, and incubated in YE medium for > 3 hr, spread onto plates containing 5 mM Rbin-1. 13 resistant
clones were isolated. Sequencing of these clones revealed that all resistant clones had a point mutation (F1093L: 6 clones, F1093S: 2
clones, F1097S: 2clones, L1335S: 2 clones, and E1044V: 1 clone) in the mdn1 gene. To re-construct these mdn1 point mutants, a
DNA fragment containing amdn1 point mutation, whichwas amplified by PCR from the genome of eachRbin-1-resistantmutant, was
transformed into the SAK72 strain. Homologous recombination between mdn1 mutant fragments and the mdn1+ gene produced
mdn1 mutant strain. Rbin-1-resistant clones were selected on 5 mM Rbin-1 containing plates. The replacement of mdn1+ gene by
mdn1 mutant was confirmed by sequencing. All resistant clones in MDR-sup background were crossed with the wild-type strain
to construct mdn1 point mutants in the wild-type background.
SAR analysis of Rbin analogs using growth assay of pombe
S.pombestrainsweregrown toexponential phaseanddiluted toOD6000.01.1ml DMSOorDMSOsolutionofRbins (1000x)weremixed
with 1 ml diluted cell suspensions. The cells were placed in shaker (220 rpm) for 18 hr at 29C till OD600 of DMSO control reached 1.
Relative growthwas calculatedbydividing themeasuredODat a specific concentration by theOD for theDMSOcontrol. Halfmaximum
growth inhibition (GI50) was determined by fitting relative growth to a four-parameter sigmoidal dose-response curve in PRISM.
Construction of full-length S. pombemdn1
For thewild-typemdn1gene,DNA fragmentswerePCR-amplified frompDUAL-YFH1c-mdn1 (gift fromMinoruYoshida) andS. pombe
genomic DNA. After ligation of DNA fragments, the full-lengthmdn1 genewas cloned into pREP1NTAPDNdeI vector or pFastBac HTC
vector. For themdn1ATPsitemutants (e. g.WalkerA,WalkerB, andRfinger),mutationswere introduced intoN (1-3355bp)orM (3350-
8528 bp) fragment of themdn1 gene using PrimeSTAR Mutagenesis Basal Kit (TAKARA), followed by ligation of N, M, and C (8523-
14154 bp) fragments. The full-lengthmdn1mutant genes were cloned into pREP1NTAPDNdeI vector or pFastBac HTC vector.
mdn1-ts complementation assay
The SAK2189 (mdn1-ts26) strain was transformed with wild-type or mutant pREP1NTAPDNdeI-mdn1 plasmid, and grown on EMM–
Leu plate containing 30 mM thiamine at 25C. Colony PCR and DNA sequencing was carried out to confirm that transformants
harbored correct plasmid DNA. 5 ml EMM–Leu pre-cultures containing 30 mM thiamine were incubated overnight at 25C up to
OD (590 nm) 0.5. Cells were washed with DDW to remove thiamine, followed by resuspension in thiamine-free EMM–Leu medium
at OD (590 nm) = 0.01. After incubation of 2 ml culture for 24 hr at 36C, OD (590 nm) values were measured.
Purification of recombinant Schizosaccharomyces pombe Mdn1
All biochemical reagents were obtained from SIGMA-ALDRICH unless specified otherwise. The cDNA encoding fission yeast Mdn1
was cloned into pFastBac HTC vector (Invitrogen). We used the Bac-to-Bac system (Invitrogen) to generate recombinant baculovi-
rus. High Five cells (Life Technologies) were grown in Sf-900 II SFM (Life Technologies 10902-096) with 1X Antibiotic-Antimyocotic
(Life Technologies) to2.5 million/mL and then infected (1:80 dilution of P2 virus). The cells were harvested 60 hr after infection. All of
the following steps were done on ice or at 4C. The cells were lysed by sonication in equal volume of lysis buffer (50mM Tris, 400mM
NaCl, 20 mM imidazole, 1 mM MgCl2, 5 mM 2-mercaptoethanol, 200 mM ATP, 3 U/mL benzonase, 1X Roche complete protease in-
hibitor without EDTA, 10% glycerol [pH 7.5]). The homogenized lysate was then centrifuged at 55,000 rpm for 1 hr. The supernatant
was incubated with Ni-NTA beads (QIAGEN) for 40 min. The beads were extensively washed using Washing buffer (50 mM Tris,
400 mM NaCl, 20 mM imidazole, 1 mM MgCl2, 5 mM 2-mercaptoethanol, 10% glycerol [pH 7.5]). The protein was then eluted by
high imidazole buffer (20 mM Tris [pH 7.5], 120 mM NaCl, 300 mM imidazole, 1 mM MgCl2, 5 mM 2-mercaptoethanol, 200 mM
ATP (A2383)). The eluted fraction was filtered and loaded onto a Mono Q column 5/50 GL (GE Healthcare Life Sciences). The protein
was eluted around 400 mM NaCl and the fractions were collected and analyzed by SDS-PAGE. The relevant fractions were pooled
and then concentrated using Amicon Ultra-4 Centrifugal Filter Units. The concentrated sample was then loaded on Superose 6, 10/
300 GL (GE Healthcare Life Sciences) using FPLC SEC buffer (20 mM Tris (pH = 7.5), 150 mM NaCl, 1 mM MgCl2, 1mM EGTA and
5 mM 2-mercaptoethanol). Peak fractions were collected and ATPase assay was carried out directly with fresh protein. Protein
concentration was determined using a Bradford assay.e2 Cell 167, 512–524.e1–e7, October 6, 2016
Radioactive ATPase Assay
Radioactive g-P32-ATP (PerkinElmer, BLU002Z250UC) was added to 600 mMMgATP (pH = 7.0) solutions at volume ratios of 1:1000-
1:300, depending on the lifetime of the radioactive reagent. The total volume of each reaction was 12 mL, including 6 ml of protein from
size exclusion chromatography fractions (final concentration 0-50 nM for different fractions, peak fractions were used for Rbin-1
and AMPPNP inhibition experiments in Figure 3E), 4 ml FPLC SEC buffer with 0.6 mM Na2SO4 and 2 ml MgATP (final concentration =
100 mM). The reactions were then incubated at room temperature for 30 or 60 min before quenching with 12 ml 0.2 M EDTA. 1 ml from
each reaction mixture was spotted on to TLC PEI cellulose F plates (Millipore, 105579). The TLC buffer contained 0.15 M formic acid
and 0.15 M lithium chloride. The TLC plates were then imaged using the Typhoon Scanner 9400 (GE Healthcare Life Sciences).
ImageJ was used to calculate the densitometric ratio of the spots corresponding to radioactive free phosphate and ATP to determine
the percent of ATP hydrolyzed.
NADH-coupled steady-state ATPase assay
For each steady-state ATPase reaction the final volume was 30 mL. The final concentration of protein was 50 nM. The FPLC SEC
buffer was used to dilute the sample. NADH (N7410), phosphoenol pyruvic acid monopotassium salt (P7127), D-lactic dehyrogenase
(L3888) and pyruvate kinase (ammonium sulfate suspension, P1506) were added to final concentration of 140 mM, 1.25mM, 40 U/mL
and 80 U/mL. 1 ml DMSO/compound solution was added andmixed. 3 ml 10 mMMgATP (pH = 7.0), was added to make the final total
volume of 30 ml and final concentration of MgATP was 1 mM. Time course of fluorescence decrease due to NADH oxidation was
measured using Synergy NEO Microplate Reader. The fluorescence values were plotted against time and fit by linear regression.
The slopes of these lines were used to calculate the ATPase rate. The relative activities were obtained by dividing the measured ac-
tivity by activity in DMSO control (no compound). The EC50 value for the inhibition of wild-type Mdn1 was determined by fitting the
average values for relative activity at each inhibitor concentration (n = 4 independent measurements) to a four-parameter sigmoidal
dose-response curve using PRISM.
Image acquisition
For all the microscopy experiments cells were fixed using methanol, stained with DAPI, imaged by amicroscope (Axio Imager 2; Carl
Zeiss) with a 63x objective (Plan-APOCHROMAT, 63x/1.4 Oil DIC; Carl Zeiss), and processed with Axio Vision 4.8 software (Carl
Zeiss). A Z-stack of 2 mm thickness, with single planes spaced by 0.3 mm, was acquired and maximum intensity projections
were generated. To compare signal intensities, all images were taken with the same exposure conditions and processed similarly.
Two hybrid analysis
The AH109 strain was co-transformed with pGBKT7-mdn1 MIDAS as the bait plasmid and pGADT7-rsa4 MIDO, pGADT7-rsa4
MIDO-E105D, or pGADT7-ytm1 MIDO as the prey plasmids. Representative transformants were spotted on SC–LeuTrp (+His)
and SC–LeuTrpHis (–His) plates in 1:5 dilution series, and incubated for 2 days at 32C.
Quantification of GFP signals in nucleoplasm and nucleolus
Interphase S. pombe cells have crescent-like shaped nucleoplasm (or DAPI-positive region) as shown in the cartoon (Figure 6A).
Because of the different orientations of cells, some interphase cells show clear crescent-shape, but the others do not in projected
single images. Therefore, for quantification, cells that showed clear crescent-shape DAPI signals were randomly chosen, and
then GFP signals in nucleoplasm (DAPI-positive region) and/or nucleolus (DAPI-negative region) were quantified. The signal intensity
of GFP signals was plotted in GraphPad Prism 6 to quantify nucleolar Rpl2501-GFP signals, and ratio of nucleoplasmic and nucleolar
Rix7-GFP signals. The ratios of nucleoplasmic and nucleolar signals of Rix7-GFP, Ppp1-GFP, Ytm1-GFP, andNsa1-GFP in Figure 6B
were calculated.
RNA analysis
Total RNA was isolated from S. pombe cells using the hot phenol method followed by phenol-chloroform extraction, precipitation,
and purification using QIAGEN RNeasy columns (Lyne et al., 2003). Northern blots were performed using the DIG Northern Starter Kit
(Roche) according to the manufacturer’s protocol. Denatured total RNAs were separated in 1.3% agarose gel containing 1.85%
formaldehyde, 20 mM MOPS, 5 mM sodium acetate, and 1 mM EDTA. To detect abundant rRNAs (25S, 18S, and 5.8S), gels
were stained by GelRed (Biotium). For Northern blotting, gels were transferred to positively charged nylon membrane (Hybond-N,
GE Healthcare) using Whatman TurboBlotter Transfer System (Fisher Scientific). After RNAs were fixed to the membrane by UV-
crosslinking (120 mJ), the membrane was incubated with hybridization buffer (DIG Easy Hyb Granules with 0.1 mg/ml Poly (A) and
5 mg/ml Poly (dA)) for blocking at 40C for 30 min, and then with hybridization buffer containing 21.7 pmol digoxigenin (DIG)-labeled
probes generated using DIG Oligonucleotide Tailing Kit, 2nd generation (Roche) at 40C for 6 hr. The primers for generating probes
were 1005 (50- CTTAGACATGCATGGCT30), 1006 (50- GCGCTTATTGATATGCTT30), 1007 (50- CATTTCGCTGCGTTCTT30), and
1005 (50- TCGTTCAACACCTCATC30). The hybridized probes were immunodetected with anti-DIG-AP, Fab fragments (Roche) and
were then visualized with the chemiluminescence substrate CDP-Star.Cell 167, 512–524.e1–e7, October 6, 2016 e3
Immunoprecipitation
Cells expressing Rix1-5FLAG or Nsa1-5FLAG were harvested and washed using STOP buffer (150 mM NaCl, 50 mM NaF, 10 mM
EDTA, 1mM NaN3 [pH 8.0]). Cell pellet was mixed with equal amount of buffer 1 (50 mM Tris-HCl (pH 7.5), 300 mM NaCl, 1.5 mM
MgCl2, 0.3%NP-40, 1mMPMSF, 1mMDTT, 0.1mMNa3VO4, protease inhibitor mix (Sigma)), and themixture was beaten with glass
beads using Fastprep bead-beater. Buffer 2 (50mMTris-HCl (pH 7.5), 1.5mMMgCl2, 7.5%glycerol, 1mMPMSF, 1mMDTT, 0.1mM
Na3VO4, protease inhibitor mix (Sigma)) was added in volumes 2x the cell pellet, and the mixture was centrifuged (5k rpm, 2 min
once, and 14k rpm, 10 min twice) to obtain supernatants (whole cell extracts). Immunoprecipitation was performed by incubating
the whole cell extracts with anti-FLAG M2 monoclonal antibody (Sigma) and Dynabeads Protein G (Veritas) for 1 hr at 4C. Whole
cell extracts and immunoprecipitates were subjected to immunoblot analysis using mouse anti-HA monoclonal antibody 12CA5
(abcam), mouse anti-FLAG M2 monoclonal antibody (Sigma), or anti-GFP monoclonal antibody (Roche).
General Synthesis Information
Materials and instrumentation
Materials were purchased from Sigma-Aldrich and used without purification, unless otherwise noted. Reactions were run in capped
roundbottomflasks stirredwithTeflon-coatedmagnetic stir bars.Moisture- andair-sensitive reactionswereperformed in flame-dried
round bottom flasks, fitted with rubber septa or glass gas adapters, under a positive pressure of nitrogen. Moisture- and air-sensitive
liquidsorsolutionswere transferredvianitrogen-flushedsyringes.Asnecessary, solutionsweredeoxygenatedbybubblingwithnitrogen
usingagasdispersion tube. Evaporationof solventswasaccomplishedby rotary evaporation usingaBu¨chi rotaryevaporator, equipped
with a dry ice-acetone condenser, at 5-75mmHg at temperatures between 35C and 50C. Experiments were monitored by thin layer
chromatography (TLC)or liquidchromatographymassspectrometry (LC-MS).Themaintenanceof30Cto150Creaction temperatures
was accomplished by the use of an oil bath. Products obtained as solids or high boiling oils were dried under vacuum (1 mmHg).
Chromatography
Compounds were purified using silica gel column chromatography, as necessary. Analytical TLCwas performed usingWhatman 250
micron aluminum backed UV F254 precoated silica gel flexible plates. Subsequent to elution, illumination at 254 nm allowed for visu-
alization of UV absorbing materials. Staining with basic potassium permanganate solution allowed for further visualization.
Analytical Data
Proton nuclear magnetic resonance spectra (1H NMR) were recorded on Bruker DPX 400 MHz nuclear magnetic resonance spec-
trometer. Chemical shifts for 1H NMR spectra are reported as d in units of parts per million (ppm) relative to tetramethylsilane
(d 0.0) using the residual solvent signal as an internal standard or tetramethylsilane itself: dimethylsulfoxide-d6 (d 2.50, quintet)
and deuterium oxide-d2 (d 4.80, singlet). Multiplicities are given as: s (singlet), d (doublet), t (triplet), or m (multiplet). Coupling con-
stants are reported as a J value in Hertz (Hz). The number of protons (n) for a given resonance is indicated by nH.
Liquid chromatography mass spectral analyses were obtained using aWaters MicroMassZQmass spectrometer, with an electron
spray ionization (ESI) probe, connected to aWaters 2795 HT Separation Module Alliance HT HPLC system running MassLynx (V4.0).
The system used aWaters 996 Photodiode Array Detector set to 254 nm for peak detection, and a SymmetryC18 (3.5micron) 2.13
50 mm column for separation (mobile phase for positive mode: solvent A: water with 0.1% formic acid, solvent B: acetonitrile; mobile
phase for negative mode: solvent A: water with 0.1% morpholine, solvent B: acetonitrile). Values are reported in units of mass to
charge (m/z)
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Scheme 1. Synthesis of Rbin-1 analogs
The synthesis method has been adapted from J. Comb. Chem. 2002, 4, 419-428. Briefly, a solution of thiosemicarbazide 2
(3.38mmol, 1 equivalent) in boiling water was addedwith stirring to a solution of isatin or substituted isatin 1 (3.38mmol, 1 equivalent)
in boiling ethanol. The resulting mixture was refluxed for 2h to form a precipitate of thiosemicarbazone 3, which was isolated by filtra-
tion andwashed with ethanol. Thiosemicarbazone 3, was then transferred to a solution of sodium hydroxide (3.38mmol, 1equivalent)
in water and refluxed overnight. The reactionmixture was then cooled to room temperature and the pH of the solution was adjusted to
3 with dilute aqueous HCl (1:3, v/v) to get precipitates of 5. Triazinoindole 5 was then recrystallized from ethanol or washed with hot
ethanol to get pure 5 and then dried in air.
Further elaboration of 5was achieved by the addition of the alkyl bromide 6 (0.335mmol, 0.67 equivalents) to a stirring solution of 5
(0.5mmol, 1 equivalent) in 0.1 NNaOH (aqueous) and then refluxing the resultingmixture for 2h. The precipitated product was filtered,
washed several times with water followed by hot ethanol to get pure 7.
Synthesis of indole N-subsituted Rbin-1 analog 21
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0.3 g Isatin 8 (0.2mmol, 1eq) and 0.98 g of Cs2CO3 (0.03mmol, 1.5 eq) were taken in a 25ml two-neck round bottom flask and flushed
with N2 for 30 min. 2 ml anhydrous DMF was added at 0
C while stirring. The resulting mixture was stirred for another 15 min at 0C
and warmed to room temperature and stirred for another hour. Then 4-bromo-1-butyne (0.06 ml, 3 eq) was added and stirred at 50C
overnight. After completion of the reaction 10ml of 0.2 M HCl was added to the reaction mixture and poured into a separatory funnel.
The product was extracted with 10 ml ethyl acetate (x 2) and dried over sodium sulfate. The solvent was evaporated using a rotary
evaporator and the product 9 was dried overnight under high vacuum. The product 9 was then purified using silica gel column chro-
matography using 30% hexane/ethyl acetate.
Appropriate amount of N-homopropargyl isatin 9 (0.15 mmol, 1eq), semithiocarbazide (0.165 mmol, 1.1 eq), K2CO3 (0.15 mmol,
1eq) and 4ml of water (500 ml of ethanol was added to help solubilizing isatin) were stirred and refluxed for 15 hr. The reaction mixture
was then cooled to room temperature and acidified with 1:3 (v/v) HCl (aq) to pH 2. The precipitate was filtered and washed twice
with water and once with ethanol. The product 10 was dried under vacuum.
13 ml of 3-Bromo-2-methyl propene (0.12 mmol, 1 eq) was added to a stirring solution of 0.03 g N-homopropargyl triazinoindole 10
in 0.1 M aqueous NaOH at refluxing temperatures. The resulting mixture was refluxed for 3 hr, then cooled to room temperature,
filtered, and washed 3 times with water and once with ethanol. Product analog 21 was dried under vacuum.
Characterization of the Rbin analogs
All chemical structures and naming of analogs are listed in Figure S2A.
Analog 1 or Rbin-1 (AP-5): 1HNMR (400MHz, DMSO-d6) d 1.84 (s, 3H), 3.98 (s, 2H), 4.91 (s, 1H), 5.1 (s, 1H), 7.42 (t, J = 7.38Hz, 1H),
7.56 (d, J = 8.0 Hz, 1H), 7.68 (t, J = 7.54 Hz, 1H), 8.29 (d, J = 7.64 Hz, 1H). ESI-MS (m/z) [M+H]+ Calculated: 257.33, found: 257.57.Cell 167, 512–524.e1–e7, October 6, 2016 e5
e6Analog 2 (ZC-9): 1H NMR (400 MHz, DMSO-d6) d 3.96 (d, J = 6.68 Hz, 2H), 5.16 (d, J = 9.84 Hz, 1H), 5.39 (d, J = 16.8 Hz, 1H), 6.04
(m, 1H), 7.43 (t, J = 7.46 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.68 (t, J = 7.58 Hz, 1H), 8.30 (d, J = 8.0 Hz, 1H). ESI-MS (m/z) [M+H]+
Calculated: 243.30, found: 243.55.
Analog 3 (ZC11): 1H NMR (400MHz, DMSO-d6) d 1.03 (t, J = 7.28 Hz, 3H), 1.77 (m, 2H), 3.24 (t, J = 7.16 Hz, 2H), 7.43 (t, J = 7.44 Hz,
1H), 7.56 (d, J = 8.04 Hz, 1H), 7.68 (t, J = 7.6 Hz, 1H), 8.29 (d, J = 7.68 Hz, 1H). ESI-MS (m/z) [M+H]+ Calculated: 245.32, found:
245.57.
Analog 4 (AP-89): 1H NMR (400 MHz, DMSO-d6) d 3.18 (s, 1H), 4.13 (s, 2H), 7.44 (t, J = 7.4 Hz, 1H), 7.58 (d, J = 8.04 Hz, 1H), 7.7
(t, J = 7.52 Hz, 1H), 8.32 (d, J = 7.64 Hz, 1H). ESI-MS (m/z) [M+H]+ Calculated: 241.28, found: 241.53.
Analog 5 (ZC-51): 1H NMR (400 MHz, DMSO-d6) d 0.37 (m, J = 4.81 Hz, 2H), 0.58 (m, J = 5.9 Hz, 2H), 1.24 (m, 1H), 3.23 (d, J =
7.12 Hz, 2H), 7.43 (t, J = 7.43 Hz, 1H), 7.56 (d, J = 8.08 Hz, 1H), 7.68 (t, J = 7.48 Hz, 1H), 8.30 (d, J = 7.7 Hz, 1H). ESI-MS (m/z)
[M+H]+ Calculated: 257.33, found: 257.59.
Analog 6 or Rbin-3 (AP-13): 1H NMR (400 MHz, DMSO-d6) d 4.55 (s, 2H), 7.25 (t, J = 7.16 Hz, 1H), 7.32 (t, J = 7.22 Hz, 2H), 7.42
(t, J = 7.42 Hz, 1H), 7.51 (d, J = 7.24 Hz, 2H), 7.56 (d, J = 8.04 Hz, 1H), 7.68 (t, J = 7.5 Hz, 1H), 8.29 (d, J = 7.64 Hz, 1H). ESI-MS (m/z)
[M+H]+ Calculated: 293.36, found: 293.62.
Analog 7 (AP-12): 1H NMR (400 MHz, DMSO-d6) d 4.56 (s, 2H), 7.42 (t, J = 7.48 Hz, 1H), 7.52 (d, J = 4.96 Hz, 2H), 7.56 (d, J =
8.08 Hz, 1H), 7.68 (t, J = 7.62 Hz, 1H), 8.29 (d, J = 7.72 Hz, 1H), 8.50 (d, J = 3.72 Hz, 2H). ESI-MS (m/z) M+H]+ Calculated:
294.35, found: 294.59.
Analog 8 or Rbin-5 (ZC-10): 1H NMR (400 MHz, DMSO-d6) d 4.74 (s, 2H), 7.43 (t, J = 7.54 Hz, 1H), 7.49 (t, J = 3.69 Hz, 2H), 7.58
(d, J = 8.08 Hz, 1H), 7.6 (m, 2H), 7.88 (d, J = 8.08 Hz, 3H), 8.04 (s, 1H), 8.30 (d, J = 7.6 Hz, 1H). ESI-MS (m/z) M+H]+ Calculated:
243.42, found: 243.65.
Analog 9 (ZC-5): 1H NMR (400 MHz, DMSO-d6) d 3.73 (s, 3H), 4.53 (s, 2H), 6.83 (d, J = 7.2 Hz, 1H), 7.08 (d, J = 7.12 Hz, 2H), 7.24
(t, J = 7.9 Hz, 1H), 7.43 (t, J = 7.48 Hz, 1H), 7.58 (d, J = 8.04 Hz, 1H), 7.69 (t, J = 7.7 Hz, 1H), 8.31 (d, J = 7.6 Hz, 1H). ESI-MS (m/z)
[M+H]+ Calculated: 323.39, found: 323.67.
Analog 10 (ZC-41): 1H NMR (400 MHz, DMSO-d6) d 4.86 (s, 2H), 7.43 (t, J = 7.52 Hz, 1H), 7.56 (m, 2H), 7.7 (t, J = 7.72, 2H), 7.90
(d, J = 7.72 Hz, 1H), 8.05 (d, J = 8.12 Hz, 1H), 8.30 (d, J = 7.68 Hz, 1H). ESI-MS (m/z) [M+H]+ Calculated: 338.36, found: 338.61.
Analog 11 (ZC-7): 1HNMR (400MHz, DMSO-d6) d 4.69 (s, 2H), 7.44 (t, J = 7.6 Hz, 1H), 7.5 (d, J = 8.0 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H),
7.80 (d, J = 8.16Hz, 2H), 8.17 (d, J = 8.16Hz, 2H), 8.30 (d, J = 7.68Hz, 1H). ESI-MS (m/z)M+H]+Calculated: 338.36, found: 338.60.
Analog 12 or Rbin-4 (ZC-30): 1H NMR (400 MHz, DMSO-d6) d 4.59 (s, 2H), 7.16 (t, J = 7.44 Hz, 1H), 7.22 (t, J = 9.28 Hz, 1H), 7.33
(m, 1H), 7.43 (t, J = 7.48 Hz, 1H), 7.58 (d, J = 8.08 Hz, 1H), 7.64 (t, J = 7.62 Hz, 1H), 7.69 (t, J = 7.64 Hz, 1H), 8.31 (d, J = 7.72 Hz, 1H).
ESI-MS (m/z) [M+H]+ Calculated: 311.35, found: 311.57.
Analog 13 (AP-42): 1H NMR (400 MHz, DMSO-d6) d 4.63 (s, 2H), 7.04 (t, J = 7.5 Hz, 1H), 7.36 (t, J = 7.4 Hz, 1H), 7.43 (t, J = 7.5, 1H),
7.58 (d, J = 8.04 Hz, 1H), 7.69 (t, J = 6.94 Hz, 2H), 7.90 (d, J = 7.68 Hz, 1H), 8.31 (d, J = 7.64 Hz, 1H). ESI-MS (m/z) [M+H]+ Calcu-
lated: 419.26, found: 419.48.
Analog 14 (AP-43): 1H NMR (400 MHz, DMSO-d6) d 4.51 (s, 2H), 7.33 (d, J = 7.76 Hz, 2H), 7.43 (t, J = 7.46 Hz, 1H), 7.57 (d,
J = 8.0 Hz, 1H), 7.68 (t, J = 8.98 Hz, 3H), 8.30 (d, J = 7.6 Hz, 1H). ESI-MS (m/z) [M+H]+ Calculated: 419.26, found: 419.55.
Analog 15 or Rbin-2 (ZC-32): 1HNMR (400MHz, DMSO-d6) d 1.84 (s, 3H), 3.98 (s, 2H), 4.91 (s, 1H), 5.12 (s, 1H), 7.58 (d, J = 8.28Hz,
1H), 7.74 (s, 1H), 8.24 (d, J = 8.4 Hz, 1H). ESI-MS (m/z) [M]+ Calculated: 335.22, found: 335.45 and [M+2H]+ Calculated: 337.22,
found: 337.48 (bromine pattern).
Analog 16 (ZC-33): 1H NMR (400 MHz, DMSO-d6) d 4.56 (s, 2H), 7.26 (t, J = 7.24 Hz, 1H), 7.33 (t, J = 7.36 Hz, 2H), 7.51 (d, J =
7.36 Hz, 2H), 7.59 (d, J = 7.24 Hz, 1H), 7.75 (s, 1H), 8.24 (d, J = 8.32 Hz, 1H). ESI-MS (m/z) [M]+ Calculated: 371.26, found:
371.49 and [M+2H]+ Calculated: 373.26, found: 373.48 (bromine pattern).
Analog 17 (ZC-52): 1H NMR (400 MHz, DMSO-d6) d 0.37 (d, J = 4.12 Hz, 2H), 0.58 (d, J = 7.2 Hz, 2H), 1.24 (m, 1H), 3.23 (d, J =
7.04 Hz, 2H), 7.58 (d, J = 8.12 Hz, 1H), 7.73 (s, 1H), 8.24 (d, J = 8.0 Hz, 1H). ESI-MS (m/z) [M]+ Calculated: 335.22, found:
335.52 and [M+2H]+ Calculated: 337.22, found: 337.55 (bromine pattern).
Analog 18 (AP-45): 1HNMR (400MHz, DMSO-d6) d 4.63 (s, 2H), 7.04 (t, J = 7.52Hz, 1H), 7.36 (t, J = 7.4 Hz, 1H), 7.59 (d, J = 8.28Hz,
1H), 7.7 (d, J = 7.56 Hz, 1H), 7.76 (s, 1H), 7.90 (d, J = 7.84 Hz, 1H), 8.25 (d, J = 8.2 Hz, 1H). ESI-MS (m/z) [M]+ Calculated: 497.15,
found: 497.43 and [M+2H]+ Calculated: 499.15, found: 499.46 (bromine pattern).
Analog 19 (AP-46): 1H NMR (400 MHz, DMSO-d6) d 4.5 (s, 2H), 7.33 (d, J = 8.08 Hz, 2H), 7.59 (d, J = 8.28 Hz, 1H), 7.67 (d, J =
8.16 Hz, 2H), 7.75 (s, 1H), 8.24 (d, J = 8.2, 1H). ESI-MS (m/z) [M]+ Calculated: 497.15, found: 497.44 and [M+2H]+ Calculated:
499.15, found: 499.45 (bromine pattern).
Analog 20 (AP-91): 1H NMR (400 MHz, DMSO-d6) d 3.18 (s, 1H), 4.13 (s, 2H), 7.60 (d, J = 8.24 Hz, 1H), 7.74 (s, 1H), 8.26 (d,
J = 8.28 Hz, 1H). ESI-MS (m/z) [M]+ Calculated: 319.18, found: 319.49 and [M+2H]+ Calculated: 321.18, found: 321.51 (bromine
pattern).
Analog 21 or Rbin-6 (AP-38): 1H NMR (400 MHz, DMSO-d6) d 2.78 (m, 3H), 4.0 (s, 2H), 4.55 (t, J = 6.66, 2H), 4.91 (s, 1H), 5.14
(s, 1H), 7.48 (t, J = 7.46 Hz, 1H), 7.75 (t, J = 7.44 Hz, 1H), 7.90 (d, J = 8,24 Hz, 1H), 8.34 (d, J = 7.64 Hz, 1H). ESI-MS (m/z)
[M+H]+ Calculated: 309.40, found: 309.65.
Analog 22 or Rbin-7 (ZC-21): 1H NMR (DMSO) d 1.85 (s, 3H), 3.99 (s, 2H), 4.91 (s, 1H), 5.12 (s, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.96
(d, J = 8.4 Hz, 1H), 8.59 (s, 1H). ESI-MS (m/z) [M+H]+ Calculated: 383.22, found: 383.51.Cell 167, 512–524.e1–e7, October 6, 2016
Analog 23 (ZC-25): 1HNMR (400MHz, DMSO-d6) d 4.56 (s, 2H), 7.25 (t, J = 7.04Hz, 1H), 7.33 (t, J = 7.32Hz, 2H), 7.42 (d, J = 8.4 Hz,
1H), 7.51 (d, J = 7.36 Hz, 2H), 7.96 (d, J = 8.56 Hz, 1H), 8.60 (s, 1H). ESI-MS (m/z) [M+H]+ Calculated: 419.26, found: 419.48.Data reporting
Sample size was determined based on practical and experimental considerations. No statistical methods were used to predetermine
sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and
outcome assessment.
QUANTIFICATION AND STATISTICAL ANALYSIS
Unpaired t test was used for comparison between two groups whose variance is similar (calculated by F-test). Unpaired t test with
Welch’s correction was used for comparison between two groupswhose variance is different (calculated by F-test). Significance was
considered when the P-value was less than 0.05.Cell 167, 512–524.e1–e7, October 6, 2016 e7
Supplemental Figures
Figure S1. Analysis of Rbin-1-Sensitive and -Resistant mdn1 Mutants, Related to Figure 1
(A) The cut2-364 (cut2ts) strain shows higher sensitivity to Rbin-1 than wild-type (WT). Exponentially growing culture (OD = 0.5) ofWT (black circle) and cut2ts (gray
square) cells were diluted 50 times in YE4S medium and treated with Rbin-1, and incubated for 17 hr at 29C. Growth (%) is presented relative to DMSO-treated
cells.
(B) Schematic shows potential difference betweenwild-type (WT) and cut2-364 (cut2ts) strains. X indicates backgroundmutations in cut2-364 strain. Y indicates a
mutation in the cut2 gene. ‘‘cut2ts-rev’’ strain was constructed by utilizing homologous recombination between cut2-364 mutation and cut2 (WT) fragments.
(C and D) A point mutation in the mdn1 gene (L1113F) confers Rbin-1 sensitivity. Exponentially growing culture (OD = 0.5) of wild-type (square), kan < < mdn1+
(triangle), and kan < <mdn1 (L1113F) (circle) cells were diluted 50 times in YE4Smedium and treated with RBin-1(C) or cycloheximide (D), and incubated for 17 hr
at 29C. Growth (%) is presented relative to DMSO-treated cells.
(E) Overexpression of Mdn1mutants (F1093L or D1123E) confers Rbin-1 resistance. Exponentially growing culture of MDR-sup strains, in whichwild-type (WT) or
mutants (F1093L or D1123E) of full-lengthMdn1, or vector control (-) were overexpressed (from the nmt1 promoter), were diluted 25 times in EMM-Lmedium and
treated with 1 mM Rbin-1, and incubated for 18.5 hr at 32C. Growth (%) is presented relative to DMSO-treated cells.
A C
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Figure S2. Analysis of Rbin-1 Analogs, Related to Figure 1
(A) Structure-activity relationship of Rbin analogs (summary is provided in Figure 1I). Compounds were added to wild-type cells in diluted culture (in logarithmic
phase, OD600 0.01) and the mixture was incubated for 18 hr at 29C till OD600 = 1 for DMSO control. Half maximum growth inhibition (GI50, mean ± SD, at
least three independent experiments) was determined by fitting relative growth to a four-parameter sigmoidal dose-response curve in PRISM. For compounds
that inhibited growth by less than 50% at 500 nM or 2500 nM we indicate GI50 to be ’’R 500 nM’’ or ’’R 2500 nM’’ respectively. For some compounds dose-
dependent inhibition could not be readily fit to standard equations, likely due to limited compound solubility (indicated as n.d.).
(B) Growth inhibition by Rbin analogs at 500 nM. Growth (%) is presented relative to DMSO-treated cells (mean ± SDs, three independent experiments, 500 nM
data points for Rbin-1 and RBin-2 are the same as those in panels C and D).
(C) Three examples of dose-dependent inhibition of yeast growth by Rbin analogs (mean±SDs, three independent experiments, the curves are fitted by the four-
parameter sigmoidal function as in [A]).
(D) Rbin-2 is more toxic to the RBin-1-sensitive strain (L1113F mutation in Mdn1) compared to WT cells and significantly less toxic to a Rbin-1-resistant strain
(L1093F mutation in Mdn1) (mean±SDs, three independent experiments, the curves are fitted by the four-parameter sigmoidal function as in [A]).
Figure S3. Construction of mdn1-ts26 Mutant, Related to Figure 2
(A) The mutations inmdn1-ts26 strain are shown. I3280M (red color) is the critical mutation that causes temperature sensitivity, since reversing only this mutation
(I3280M was mutated to the original isoleucine) abolished temperature sensitivity (mdn1ts26-IMI in Figure 2C).
(B) Growth curve of wild-type (WT) and mdn1-ts26 cells at 36C (mean±SDs, three independent experiments).
Figure S4. Purification of Recombinant Full-Length Mdn1 with the F1093L Point Mutation, Related to Figure 3
(A) Size-exclusion chromatography elution profile of recombinant F1093L Mdn1.
(B) Mass spectrometry analysis of the single band from Figure 3H identified 256 peptides from F1093L Mdn1. (coverage: 71.5%). Green and yellow regions
represent matched peptides with 1% and 5% false discovery rate, respectively (figure generated using Proteome Discoverer 1.4, Thermo Scientific).
Figure S5. Analysis of Mdn1 Function Using Rbin-1 and a Temperature-Sensitive mdn1-ts26 Mutant, Related to Figure 4
(A) Schematic for pre-rRNA processing. Positions of probes for Northern blot analyses are shown.
(B) Exponentially growing culture of wild-type (WT) and the mdn1-F1093L cells were treated with or without Rbin-1 (1 mM) for 45 min at 32C. Total RNA was
isolated and analyzed by Northern blot. Detected rRNAs and the probes used for northern blots (1005–1007 and 1009) are indicated.
(C) Exponentially growing culture of wild-type (WT) and mdn1-ts26 (ts) cells were incubated for 6 hr at 36C. Total RNA was isolated and analyzed by Northern
blot. Detected rRNAs are indicated.
Figure S6. Additional Analysis of the Rix1 Particles, Related to Figure 5
(A) Whole cell extracts were prepared from cells expressing Rix1-5FLAG. Rix1-5FLAG was immunoprecipitated with anti-FLAG antibody. Co-immunoprecipi-
tated proteins were analyzed by SDS-PAGE and Coomassie staining. Indicated protein bands were identified by mass spectrometry.
(B) Co-immunoprecipitation of Rix1-5FLAG and Ytm1-3HA. Whole cell extract (input) were prepared from cells treated with Rbin-1 (1 mM) for indicated time. Rix1-
5FLAGwas immunoprecipitated with anti-FLAG antibodies (IP: FLAG). The indicated proteins were analyzed by SDS-PAGE andwestern blotted using anti-FLAG
and anti-HA antibodies. Representative images are shown. The grouping of images from different parts of the same gel is indicated by dividing lines. The graphs
show relative amount of Ytm1 in IP samples. (Error bars represent SD (n = 3)).
Figure S7. Additional Analysis of the Nsa1 Particle, Related to Figure 6
(A) Whole cell extract (Input) were prepared from cells treated with (+) or without (-) Rbin-1 (1 mM) for 30 min at 29C. Rix1-5FLAG or Nsa1-5FLAG was immu-
noprecipitated with anti-FLAG antibodies (IP: FLAG). The indicated proteins were analyzed by SDS-PAGE and western blotting using anti-FLAG and anti-GFP
antibodies.
(B) Nsa1-5FLAG or Rix1-5FLAG was immunoprecipitated with anti-FLAG antibody from cells treated with (+) or without (-) Rbin-1 (1 mM) for 30 min at 29C. IP
samples were analyzed by SDS-PAGE and ORIOLE staining. Mdn1 bands in the Rix1-5FLAG IP sample were identified by mass spectrometry. The band
indicated by yellow asterisk is likely Mdn1 by molecular weight. Confirmation of this band by mass spectrometry failed, likely due to low protein levels. Rbin-1
treatment did not change overall composition of Rix1- and Nsa1-particles, while Mdn1 in the Nsa1-particle is likely reduced by Rbin-1 treatment.
(C) Co-immunoprecipitation of GFP-Mdn1 and Nsa1-5FLAG. Whole cell extract (Input) were prepared from cells expressing GFP-Mdn1. Nsa1-5FLAG or GFP-
Mdn1 was immunoprecipitated with anti-FLAG, monoclonal anti-GFP (mono), or polyclonal antibodies anti-GFP (poly) antibodies. GFP-Mdn1 was analyzed by
SDS-PAGE and western blotted using anti-GFP antibody.
